LONG Gong-bo，SUN Chen，LI Jian，CAO Yu，ZHOU Bing*

    (School of Life Sciences，Tsinghua University，Beijing 100084，China)

    [Abstract] Artemisinin is a key anti-malarial drug and few clinically meaningful resistant cases about its application have so far been reported. The World Health Organization (WHO) officially recommended the use of ACT (Artemisinin-based Combination Therapy) as the first line antimalarial application to increase its inhibitory efficacy and prevent the likely resistance development. Based on our current understanding of artemisinin ......